• Publications
  • Influence
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
It is shown that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
  • J. Byrd, Jennifer R Brown, +32 authors P. Hillmen
  • Medicine
    The New England journal of medicine
  • 11 July 2014
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
Using genomic-scale gene expression profiling, CLL is characterized by a common gene expression “signature,” irrespective of Ig mutational status, suggesting that CLL cases share a common mechanism of transformation and/or cell of origin.
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Although the presence of an unmutated IgV(H) gene is strongly associated with the expression of Zap-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from
Although the prognostic impact of many recurring abnormalities has not been ascertained independently of complex karyotype, cytogenetics is among the most useful factors predicting attainment of CR, CIR, and long-term survival in adult AML.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Alemtuzumab induced significant responses in patients with relapsed or refractory B-cell chronic lymphocytic leukemia with clinical benefit in the majority and with acceptable toxicity in a high-risk group.
Adult Burkitt leukemia and lymphoma.
Although Burkitt lymphoma cells are extremely chemosensitive, biologically targeted therapies should be developed because current treatment options are suboptimal for patients with poor prognostic features or in the setting of relapsed disease.
Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review.
The clinical significance of EML in patients with ANLL treated with modern chemotherapy or bone marrow transplantation is needed and the addition of immunohistochemical stains can assist in preventing such misdiagnoses.